News | December 22, 2024
Laurus Labs informs that Eight Roads Ventures and F-Prime Capital (Investors) have together invested Rs. 120 crores in Laurus Bio
The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
Merck will record a pre-tax charge relating to the upfront payment of $588 million
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
This facility marks a significant milestone in transforming the global food industr
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Difluprednate Ophthalmic Emulsion, 0.05% is a topical corticosteroid that is indicated in the treatment of inflammation and pain associated with ocular surgery
Merck has also decided to end the favezelimab clinical development program
Subscribe To Our Newsletter & Stay Updated
